AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15492306 — intervention group
Group type: COMPARATOR
Intervention: Shock (n=321)
Number of subjects: 634
Study 11256459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 11256459 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0
Study 11256459 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy
Number of subjects: 0
Study 11256459 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation, group therapy, couples therapy, family therapy, interpersonal psychotherapy
Number of subjects: 0
Study 9365866 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7943089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (10 mg, 10 mg, 5 mg, 5 mg) administered in four doses at 12-hour intervals over 36 hours
Number of subjects: 40
Study 7943089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 40
Study 2975609 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200-600 mg daily
Number of subjects: 30
Study 2975609 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 12.5-37.5 mg daily
Number of subjects: 30
Study 29695707 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice consumed with 3 meals/day (WM)
Number of subjects: 26
Study 29695707 — intervention group
Group type: COMPARATOR
Intervention: Orange juice consumed in-between 3 meals/day (BM)
Number of subjects: 26
Study 28286289 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg immediate release Stilnox®
Number of subjects: 0
Study 28286289 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5mg modified release Ambien® CR
Number of subjects: 0
Study 28286289 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg intravenous zolpidem
Number of subjects: 0
Study 25781379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention including one nurse-patient meeting before leaving the ED and two additional telephone contacts over the next 2 weeks.
Number of subjects: 265
Study 25781379 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving usual care without the nursing intervention.
Number of subjects: 265
Study 23860220 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic cellulose wound dressing (BWD) + foam (study group)
Number of subjects: 46
Study 23860220 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing (control group)
Number of subjects: 46
Study 21146937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (25-200mg/day) plus naltrexone (50mg/day)
Number of subjects: 62
Study 21146937 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus naltrexone (50mg/day)
Number of subjects: 62
Study 18518938 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole group (100 mg levamisole p.o. after each haemodialysis session)
Number of subjects: 70
Study 18518938 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo instead of levamisole)
Number of subjects: 70
Study 16598663 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with offences against biological daughters or stepdaughters
Number of subjects: 291
Study 16598663 — intervention group
Group type: COMPARATOR
Intervention: Men with offences against otherwise‐related or unrelated girls
Number of subjects: 291
Study 16598663 — intervention group
Group type: COMPARATOR
Intervention: Men with no offences against girls
Number of subjects: 291
Study 12687818 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Closed-loop Stimulation (ECLS)
Number of subjects: 10
Study 12687818 — intervention group
Group type: COMPARATOR
Intervention: Standard Closed-loop Stimulation (SCLS)
Number of subjects: 10
Study 12687818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECLS and SCLS
Number of subjects: 10
Study 10890312 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lithium carbonate for 10 days and 30 mg mirtazapine on day 9
Number of subjects: 12
Study 10890312 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules and 30 mg mirtazapine on day 9
Number of subjects: 12
Study 10890312 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine and lithium
Number of subjects: 12
Study 10890312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 12
Study 8715878 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education (CE) program on stoma care
Number of subjects: 51
Study 8715878 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction survey during the course, on completion, and four months after the course
Number of subjects: 51
Study 8715878 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 1383416 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon treatment
Number of subjects: 67
Study 1383416 — intervention group
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Number of subjects: 67
Study 1383416 — intervention group
Group type: EXPERIMENTAL
Intervention: liver biopsy
Number of subjects: 67
Study 1383416 — intervention group
Group type: COMPARATOR
Intervention: conventional techniques
Number of subjects: 67
Study 1383416 — intervention group
Group type: EXPERIMENTAL
Intervention: alanine aminotransferase values
Number of subjects: 67
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid
Number of subjects: 10
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 10
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 10
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 10
Study 6417728 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 10
Study 6417728 — intervention group
Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 10
Study 31211741 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole or exemestane (5 years of adjuvant therapy)
Number of subjects: 883
Study 31211741 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 883
Study 30112584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional care (up-titrated antihypertensive therapy with a single pill combination of olmesartan, amlodipine, and/or hydrochlorothiazide in 4-week intervals)
Number of subjects: 139
Study 30112584 — intervention group
Group type: COMPARATOR
Intervention: Standard care (treatment according to the 2013 European Society of Cardiology guidelines)
Number of subjects: 139
Study 30112584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional care
Number of subjects: 139
Study 30112584 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study 26946077 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 511
Study 26946077 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 511
Study 24521173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision by OMS teacher
Number of subjects: 0
Study 24521173 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision by teaching assistant
Number of subjects: 0
Study 24521173 — intervention group
Group type: COMPARATOR
Intervention: No supervision
Number of subjects: 0
Study 24521173 — intervention group
Group type: COMPARATOR
Intervention: Support from simulator technician
Number of subjects: 0
Study 19396322 — intervention group
Group type: EXPERIMENTAL
Intervention: PHF on-line acetate-free dialysate
Number of subjects: 35
Study 19396322 — intervention group
Group type: COMPARATOR
Intervention: Conventional bicarbonate dialysate
Number of subjects: 35
Study 19396322 — intervention group
Group type: EXPERIMENTAL
Intervention: PHF on-line with conventional dialysate
Number of subjects: 35
Study 15799802 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterjet dissection
Number of subjects: 30
Study 15799802 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic aspirator
Number of subjects: 30
Study 11524581 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 155
Study 11524581 — intervention group
Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 155
Study 9610089 — intervention group
Group type: COMPARATOR
Intervention: Maternal and cord blood magnesium levels
Number of subjects: 52
Study 9610089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in newborns weighing less than 3 kgs
Number of subjects: 52
Study 9610089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in primiparas
Number of subjects: 52
Study 9610089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood magnesium levels in mothers aged less than 20 years
Number of subjects: 52
Study 9610089 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between magnesium and zinc
Number of subjects: 52
Study 9610089 — intervention group
Group type: COMPARATOR
Intervention: Comparison of magnesium levels between male and female children
Number of subjects: 52
Study 8629744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus diclofenac (150 mg)
Number of subjects: 40
Study 8629744 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus diclofenac (150 mg)
Number of subjects: 40
Study 8629744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic preparations (n-propanol and isopropanol)
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine detergent preparations
Number of subjects: 14
Study 2899107 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated bar soap
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan products
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-detergent
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic formulations
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive organisms (Staphylococcus aureus and Candida albicans)
Number of subjects: 14
Study 2899107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-negative bacilli (GNB) residents (Acinetobacter calcoaceticus and Enterobacter spp.)
Number of subjects: 14
Study 2899107 — intervention group
Group type: COMPARATOR
Intervention: Isolation unit handwashing/disinfection
Number of subjects: 14
Study 12564085 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29893452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron
Number of subjects: 0
Study 29893452 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ondansetron
Number of subjects: 0
Study 26876066 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-guided therapy (HD)
Number of subjects: 144
Study 26876066 — intervention group
Group type: COMPARATOR
Intervention: Empiric therapy (GE)
Number of subjects: 144
Study 24460223 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppress intrusive thought for one minute
Number of subjects: 1427
Study 24460223 — intervention group
Group type: COMPARATOR
Intervention: Monitor intrusive thought for one minute
Number of subjects: 1427
Study 24460223 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppress intrusive thought effort
Number of subjects: 1427
Study 24460223 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived difficulty in controlling intrusive thought
Number of subjects: 1427
Study 24460223 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of thought's recurrence
Number of subjects: 1427
Study 24460223 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of thought's recurrence
Number of subjects: 1427
Study 22399096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 50 mg losartan and 12.5 mg HCTZ (n=109)
Number of subjects: 216
Study 22399096 — intervention group
Group type: COMPARATOR
Intervention: High-dose therapy with 100 mg losartan (n=107)
Number of subjects: 216
Study 21291036 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Pregnancy Virtual Patient program (n = 12)
Number of subjects: 23
Study 21291036 — intervention group
Group type: COMPARATOR
Intervention: Traditional clerkship (n = 11)
Number of subjects: 23
Study 18415831 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback letters to physicians
Number of subjects: 131
Study 18415831 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback letters to pharmacists
Number of subjects: 131
Study 18415831 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians)
Number of subjects: 131
Study 18415831 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacists)
Number of subjects: 131
Study 16188740 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) treatment
Number of subjects: 18
Study 16188740 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP treatment (repeated tests)
Number of subjects: 18
Study 12462872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment (Nd:YAG-laser with water spray)
Number of subjects: 27
Study 12462872 — intervention group
Group type: COMPARATOR
Intervention: Control (scaling alone)
Number of subjects: 27
Study 10497848 — intervention group
Group type: COMPARATOR
Intervention: BHAC-DM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more)
Number of subjects: 655
Study 10497848 — intervention group
Group type: EXPERIMENTAL
Intervention: BHAC-EDM (daunorubicin 40 mg/m2/day x 4 or more, behenoyl cytarabine 200 mg/m2/day x 10 or more, 6-mercaptopurine 70 mg/m2/day x 10 or more, etoposide 100 mg/m2/day x 5)
Number of subjects: 655
Study 10497848 — intervention group
Group type: COMPARATOR
Intervention: BHAC-DM
Number of subjects: 655
Study 10497848 — intervention group
Group type: EXPERIMENTAL
Intervention: BHAC-EDM
Number of subjects: 655
Study 8756388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide and etoposide (IE)
Number of subjects: 54
Study 8756388 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and cyclophosphamide (VAdriaC)
Number of subjects: 54
Study 8756388 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy after the fifth chemotherapy cycle
Number of subjects: 54
Study 2006875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritrexim 50 mg or more twice daily
Number of subjects: 19
Study 2006875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritrexim (dosages ranged from 25 to 100 mg twice a day)
Number of subjects: 19
Study 2006875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritrexim
Number of subjects: 19
Study 6123352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 3
Study 31943529 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP patients
Number of subjects: 291
Study 31943529 — intervention group
Group type: COMPARATOR
Intervention: Control group (317 full-term pregnant women)
Number of subjects: 291
Study 31021880 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink (200 ml) 2 to 3 hours before surgery
Number of subjects: 113
Study 31021880 — intervention group
Group type: COMPARATOR
Intervention: Fasting from midnight (control group)
Number of subjects: 113
Study 29704618 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Communication Skills Training intervention
Number of subjects: 12
Study 27001260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat/high-carbohydrate (LFHC) meals
Number of subjects: 65
Study 27001260 — intervention group
Group type: COMPARATOR
Intervention: High-fat/low-carbohydrate (HFLC) meals
Number of subjects: 65
Study 24443305 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg piracetam
Number of subjects: 18
Study 22377561 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 75
Study 22377561 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75
Study 20665424 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation at nutritional doses
Number of subjects: 8938
Study 20665424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8938
Study 17052819 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant NspA vaccine (rNspA)
Number of subjects: 0
Study 17052819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17052819 — intervention group
Group type: COMPARATOR
Intervention: Commercially available quadravalent meningococcal polysaccharide vaccine (Menomune)
Number of subjects: 0
Study 15896427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated water (Verum-group: n=12)
Number of subjects: 24
Study 15896427 — intervention group
Group type: COMPARATOR
Intervention: Normal mineral water (Placebo-group: n=12)
Number of subjects: 24
Study 11814097 — intervention group
Group type: EXPERIMENTAL
Intervention: PMX-F treatment (n=7)
Number of subjects: 40
Study 11814097 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=7)
Number of subjects: 40
Study 9785065 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 120
Study 9785065 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 120
Study 9785065 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 120
Study 9785065 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study 7900617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg/day)
Number of subjects: 0
Study 7900617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 0
Study 7900617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2707929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesosteine (900 mg/day)
Number of subjects: 0
Study 2707929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 782135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (Becotide) 300 mug/day
Number of subjects: 39
Study 782135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30381885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal standardized photographs
Number of subjects: 192
Study 30381885 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera angulation deviation
Number of subjects: 192
Study 30381885 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera angulation change
Number of subjects: 192
Study 27859798 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding communication
Number of subjects: 0
Study 27859798 — intervention group
Group type: COMPARATOR
Intervention: Persuasive communication
Number of subjects: 0
Study 26176313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with reduced glutathione (n=262)
Number of subjects: 505
Study 26176313 — intervention group
Group type: COMPARATOR
Intervention: Hydration alone (Control group, n=243)
Number of subjects: 505
Study 26176313 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis by percutaneous coronary intervention
Number of subjects: 505
Study 23062791 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) - flexible morning dose (30, 50, 70 mg/day)
Number of subjects: 26
Study 23062791 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 26
Study 23062791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21857357 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV (efavirenz)
Number of subjects: 0
Study 19288980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk (CM) desensitization protocol, starting with one drop of whole CM diluted 1:25, doubled weekly for 18 weeks to achieve 200 mL intake.
Number of subjects: 13
Study 19288980 — intervention group
Group type: COMPARATOR
Intervention: Soy formula (placebo)
Number of subjects: 13
Study 16817084 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (7 ml of 5 mg/ml)
Number of subjects: 74
Study 16817084 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 74
Study 16817084 — intervention group
Group type: COMPARATOR
Intervention: Control (physiologic saline solution)
Number of subjects: 74
Study 12629559 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised strength training for 15 weeks followed by 6 months of unsupervised training
Number of subjects: 60
Study 12629559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 10688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 100
Study 10688075 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 g)
Number of subjects: 100
Study 9778494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms
Number of subjects: 6
Study 8491103 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs that modulate sleep, such as tricyclic antidepressants
Number of subjects: 0
Study 8491103 — intervention group
Group type: EXPERIMENTAL
Intervention: Other agents affecting central nervous system neurotransmitters, particularly serotonin
Number of subjects: 0
Study 2979224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 12
Study 2979224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 12
Study 2979224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30714999 — intervention group
Group type: EXPERIMENTAL
Intervention: Below elbow cast (BEC)
Number of subjects: 353
Study 30714999 — intervention group
Group type: COMPARATOR
Intervention: Above elbow cast (AEC)
Number of subjects: 353
Study 28051874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart+ App (Quantum Code Technology™)
Number of subjects: 20